Macupatide + Eloralintide for Obesity

This trial tests two treatments, macupatide and eloralintide, to determine their safety and effectiveness in helping people with obesity or overweight lose weight. Participants will receive various combinations of these treatments or a placebo to compare effects. The trial aims to assess the treatments' effectiveness in individuals without type 2 diabetes. Suitable candidates include those who have struggled with obesity and do not have type 2 diabetes or a history of certain heart conditions. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that any medications you are currently taking should be at a stable dose for at least 3 months before you start the trial.

Previous studies have tested both macupatide and eloralintide for safety in humans. Research shows that eloralintide is generally well-tolerated. Specifically, after 48 weeks, it resulted in significant weight loss without major safety concerns, as noted in source 5. Most participants experienced only mild to moderate side effects.

Macupatide has also undergone safety evaluation and is being studied for its potential to aid weight loss in people with obesity. Although detailed safety information for macupatide alone is less clear, testing with eloralintide suggests a reasonable safety profile.

Researchers are excited about Macupatide and Eloralintide for obesity because they offer a fresh approach compared to current options like diet, exercise, and medications such as orlistat, liraglutide, or phentermine. Unlike these standard treatments, Macupatide and Eloralintide are designed to be administered subcutaneously (under the skin), which may offer more consistent therapeutic effects. The combination of these two drugs targets multiple pathways involved in weight regulation, potentially making them more effective at promoting weight loss and maintaining it. Additionally, these treatments may have a unique mechanism of action that could offer benefits beyond just weight loss, such as improving metabolic health.

Research has shown that macupatide and eloralintide hold promise for weight loss. In studies, participants using these treatments lost between 9.5% and 20.1% of their body weight over 48 weeks. This trial may administer either macupatide or eloralintide alone, or a combination of both. Eloralintide targets a hormone that helps control weight, and higher doses resulted in greater weight loss. When combined with eloralintide, macupatide also contributes to significant weight reduction. These findings suggest both treatments could effectively aid weight loss in individuals with obesity.³⁴⁵⁶⁷